As of March 23, 2026, Taysha Gene Therapies's top three insider holders are R.A. Ii Session (TenPercentOwner, 8.87Mn shares), Sean P. Nolan (Chief Executive Officer, 2.91Mn shares), Paul B Manning (TenPercentOwner, 2.84Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| R.A. Ii Session | 8,871,747 | 0 | 14 Jul, 2023 | |
| Sean P. Nolan | Chief Executive Officer | 2,908,257 | 0 | 27 Jan, 2026 |
| Paul B Manning | 0 | 2,841,704 | 03 Jun, 2025 | |
| Sean P. Nolan | Chief Executive Officer | 0 | 1,535,545 | 16 Aug, 2023 |
| Kamran Alam | Chief Financial Officer | 1,442,131 | 0 | 06 Feb, 2026 |
| Paul B Manning | 1,333,333 | 0 | 01 Jul, 2024 | |
| Sukumar Nagendran | President And Head Of Rd | 1,317,389 | 0 | 27 Jan, 2026 |
| John A Iii Stalfort | 1,155,224 | 0 | 04 Jun, 2025 | |
| John A Iii Stalfort | 0 | 884,290 | 16 Aug, 2023 | |
| Suyash Prasad | Cmo And Head Of Rd | 530,589 | 0 | 07 Jul, 2022 |
| Phillip B. Donenberg | 219,954 | 0 | 04 Jun, 2025 | |
| Laura Sepp-Lorenzino | 105,843 | 0 | 04 Jun, 2025 | |
| Alison S Long | 105,843 | 0 | 04 Jun, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 04 Feb, 2026 | Kamran Alam | Common Stock | D | 1,655 | $4.52 | 1,442,131 | D | S |
| 23 Jan, 2026 | Sean P. Nolan | Common Stock | D | 136,789 | $4.75 | 2,949,569 | D | S |
| 23 Jan, 2026 | Sukumar Nagendran | Common Stock | D | 89,132 | $4.75 | 1,344,307 | D | S |
| 23 Jan, 2026 | Kamran Alam | Common Stock | D | 78,968 | $4.75 | 1,467,635 | D | S |
| 26 Jan, 2026 | Sukumar Nagendran | Common Stock | D | 26,918 | $4.61 | 1,317,389 | D | S |
| 26 Jan, 2026 | Sean P. Nolan | Common Stock | D | 41,312 | $4.61 | 2,908,257 | D | S |
| 26 Jan, 2026 | Kamran Alam | Common Stock | D | 23,849 | $4.61 | 1,443,786 | D | S |
| 12 Jan, 2026 | Sean P. Nolan | Common Stock | A | 1,008,000 | $0.00 | 3,086,358 | D | A |
| 12 Jan, 2026 | Kamran Alam | Common Stock | A | 359,000 | $0.00 | 1,546,603 | D | A |
| 12 Jan, 2026 | Sukumar Nagendran | Common Stock | A | 111,324 | $0.70 | 1,117,763 | D | M |
| 12 Jan, 2026 | Kamran Alam | Employee Stock Option (right to buy) | A | 231,000 | $0.00 | 231,000 | D | A |
| 12 Jan, 2026 | Sukumar Nagendran | Common Stock | A | 88,676 | $1.71 | 1,206,439 | D | M |
| 12 Jan, 2026 | Sukumar Nagendran | Common Stock | D | 200,000 | $4.71 | 1,006,439 | D | S |
| 12 Jan, 2026 | Sean P. Nolan | Employee Stock Option (right to buy) | A | 648,000 | $0.00 | 648,000 | D | A |
| 12 Jan, 2026 | Sukumar Nagendran | Common Stock | A | 427,000 | $0.00 | 1,433,439 | D | A |
| 12 Jan, 2026 | Sukumar Nagendran | Employee Stock Option (right to buy) | D | 111,324 | $0.00 | 111,359 | D | M |
| 12 Jan, 2026 | Sukumar Nagendran | Employee Stock Option (right to buy) | D | 88,676 | $0.00 | 474,941 | D | M |
| 12 Jan, 2026 | Sukumar Nagendran | Employee Stock Option (right to buy) | A | 274,000 | $0.00 | 274,000 | D | A |
| 28 Nov, 2025 | Sukumar Nagendran | Common Stock | A | 70,172 | $0.70 | 1,076,611 | D | M |
| 28 Nov, 2025 | Sukumar Nagendran | Common Stock | A | 39,953 | $1.71 | 1,116,564 | D | M |